Navigation Links
DuraHeart™ Third-Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio-thoracic Surgery
Date:10/14/2009

Terumo Heart, Inc., a wholly owned subsidiary of Terumo Corporation, today announced it will feature the latest developments in its advanced DuraHeart™ Left-Ventricular Assist System at the 23rd Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS), Vienna, Austria, October 17-21.

Ann Arbor, Mich. (PRWEB) -- Terumo Heart, Inc., a wholly owned subsidiary of Terumo Corporation, today announced it will feature the latest developments in its advanced DuraHeart™ Left-Ventricular Assist System at the 23rd Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS), Vienna, Austria, October 17-21.

The DuraHeart LVAS is a third-generation mechanical circulatory support device designed for long-term patient use. The DuraHeart LVAS incorporates a centrifugal flow rotary pump with an active magnetically levitated impeller featuring three position sensors and magnetic coils to optimize blood flow, while minimizing device wear and tear.

The DuraHeart LVAS carries a CE Mark and is commercially available in Europe. It is currently being evaluated in the DuraHeart Pivotal U.S. Trial for Bridge to Transplant. The 140-patient U.S. trial will involve up to 40 centers. The device has also completed its clinical trial enrollment for its future submission for review and approval in Japan.

"The DuraHeart LVAS is unique when compared to second-generation devices which use mechanical bearings within the blood chamber to provide circulatory support," said William Pinon, President and CEO, Terumo Heart. "Our technology delivers magnetic levitation for a friction-free environment that ensures long-term durability. In fact, to date our data set includes more than 78 combined patient years with some of our earliest patients remaining on the device for over four years."

The DuraHeart LVAS offers competitive advantages over existing technology. The impeller's magnetic levitation eliminates premature friction wear and allows a wide gap between blood contact surface areas, enabling blood to flow through the pump unimpeded in a smooth non-turbulent fashion. In addition, a hydrodynamic failsafe, that enables the pump to continue working under conditions that might cause other devices to fail, provides reassurance to patients and physicians.

"We are excited to bring DuraHeart to our customers during this important meeting," said Pinon. "As we expand our clinical experience worldwide and prepare to engage new centers in new markets, feedback from our customers will ensure we stay on track and offer the best treatment option."

The EACTS meeting offers Terumo Heart an excellent opportunity to showcase its unique technology and gather valuable feedback from cardiac surgeon customers in the field of Heart Failure surgery. To learn more about the DuraHeart LVAS program, please visit Terumo Heart representatives at exhibit booth number 32 during the meeting.

About Heart Failure
More than 22 million people suffer from heart failure worldwide with approximately one million new patients diagnosed annually. In the setting of an aging global population, heart failure is the number one reason for hospitalization. The most severely ill patients need heart transplants in order to recover. More than 8,000 people worldwide are on the list of eligible candidates for heart transplants annually, but less than 3,000 will receive a transplant each year. A large number of people who suffer from severe heart failure do not qualify for transplantation due to other health issues. An alternative for these patients is access to artificial mechanical assist devices. Left Ventricular Assist Systems are a type of mechanical circulatory device specifically designed to improve the quality of life of the patients waiting for donor hearts, as well as those who are ineligible for a heart transplant.

About Terumo Heart, Inc.
Terumo Heart, Inc. is a U.S. subsidiary of Terumo Corporation with headquarters and manufacturing facilities in Ann Arbor, Michigan. The company's focus is the innovation and introduction of products to improve the quality of healthcare for heart failure patients. Terumo Corporation, located in Tokyo, Japan, is a leading developer, manufacturer and global marketer of a wide array of medical products. DuraHeart is limited to investigational use only in the United States, and is CE marked in Europe. For more information visit www.terumoheart.com.

###

Read the full story at http://www.prweb.com/releases/2009/10/prweb3042904.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Terumo Heart, Inc.'s DuraHeart™ Left-Ventricular Assist System Featured at Future of Health Technology Summit
2. AGA Medical Corporation Receives Approval for the AMPLATZER Muscular Ventricular Septal Defect Occluder
3. Breaking Study: Masimo Pleth Variability Index (PVI) Shown Effective in Noninvasive Detection of Changes in Ventricular Preload and Fluid Volume
4. URGENT Thoratec Corporation Worldwide Recall of Implantable Ventricular Assist Device
5. Improving survival rates among users of left ventricular assist devices
6. First Implant of DuraHeart(TM) Left Ventricular Assist System (LVAS) in Japanese Clinical Trial
7. Heart Failure Patients With Normal Left Ventricular Ejection Fraction Dont Benefit From Treatment With Angiotensin II Receptor Blocker
8. Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia
9. Hahnemann University Hospital Awarded Certification From the Joint Commission for Ventricular Assist Devices
10. Expert consensus on catheter ablation of ventricular arrhythmias
11. MitraClip(R) Therapy Data Demonstrate Significant Left Ventricular Reverse Remodeling in Patients With Sustained Reduction of Mitral Regurgitation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... ... Nutrition into the Food & Beverage and Dietary Supplement ... partner throughout Canada and USA geographies east of the Rocky Mountains since 2012. ...
(Date:2/8/2016)... ... 2016 , ... Brenton Engineering , powered by Pro ... wrapped products at WestPack 2015, February 9-11, in Anaheim, California. This new solution ... or fully-automatic case packing with a small footprint, rugged, highly flexible, and cost-effective ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local ... the greater Venice, FL area, has initiated a fundraiser for a two year ... just four days after Christmas. To support this beautiful child who is facing ...
(Date:2/8/2016)... ... ... FileHold's document management software has been implemented by DocuSyst ... for FileHold software that is pay per user subscription-based and also does on-premise ... web services API. DocuSyst also advises clients on fully functioning back up technologies ...
(Date:2/8/2016)... ... February 08, 2016 , ... Joshua Rosenthal, PhD, ... healthcare companies can use newly released government data on populations and physicians to ... intervene and capture the value they create to succeed in new economic models ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 2016  Sangamo BioSciences, Inc. (NASDAQ: SGMO ... that the U.S. Food and Drug Administration (FDA) ... application for SB-318, a single treatment strategy intended ... I (MPS I). The SB-318 IND application is ... Phase 1/2 clinical study (SB-318-1502) designed to assess ...
(Date:2/8/2016)... BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced ... Food and Drug Administration (FDA) on February 4, 2016, ... on the clinical studies being conducted under the Company,s ... hold impacts part of the clinical work currently being ... clinical trials. --> ...
(Date:2/5/2016)... Feb. 5, 2016 Amgen (NASDAQ: AMGN ) ... Global Healthcare Conference at 9:15 a.m. ET on Wednesday, Feb. ... David W. Meline , executive vice president and chief ... audio of the presentation can be accessed from the Events ... replay of the webcast will also be available on Amgen,s ...
Breaking Medicine Technology: